Impact BioMedical, Inc. (IBO) Market Cap to Earnings

Corporate emblem and logo of Impact BioMedical Inc (IBO)

Impact BioMedical Inc (IBO) delegates primary compound testing to external contractors to minimize operating expenses. A high barrier to entry is ensured by an extensive array of proprietary rights for innovative treatments. The company's price chart demonstrates the 23.00 metric, visualizing market dynamics. Meanwhile, the business relies on Stability venture research, where the absence of regular profits and R&D expenditures render cash flow unpredictable.

IBO: Impact BioMedical, Inc. P/E Multiple 09/17/2024 - 11/12/2026

Analytical breakdowns for Impact BioMedical Inc

- share price and expert price forecast:
Price Performance Chart Impact BioMedical, Inc.|IBO - Price Target Chart
- market capitalization details:
Market Value Impact BioMedical Inc|IBO - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Price of a Share Impact BioMedical|IBO - Book Capitalization|Market Value to Book Value impactbiomedinc.com|IBO - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Impact BioMedical Inc|IBO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital impactbiomedinc.com|IBO - Company Aggregate Debts|Debts to Net Assets Impact BioMedical Inc|IBO - Company Long-Term Debt|Company Current Liabilities Impact BioMedical|Critical Liquidity Ratio impactbiomedinc.com
- earnings and valuation multiples information:
IBO - Net Profit|Projected Future Earnings Impact BioMedical Inc|IBO - P/E Multiple|Projected Price to Earnings Impact BioMedical, Inc.|IBO - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Impact BioMedical Inc|IBO - Operating profit before deduction of amortization|Earnings per share for the trailing year Impact BioMedical|IBO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months impactbiomedinc.com|IBO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Impact BioMedical Inc
Summary company analysis:Impact BioMedical Inc
Original product of Impact BioMedical, Inc.

The P/E ratio determines the market value of one dollar of a company's net profit. The price-to-earnings dynamics of a company reflect current investor expectations regarding future earnings. The calculation is based on dividing the current market capitalization by annual net income. For Impact BioMedical Inc (IBO), this indicator loses its classical meaning due to the absence of commercial products. At the R&D stage of botanical extract research, the metric merely reflects a speculative valuation of potential.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio Kenvue (KVUE)|VRNA - Market Cap to Earnings|Jyong Biotech Corp - Price to Earnings Ratio|Market Price to Net Income Ratio LGND (Ligand Corp)|Amneal Pharmaceuticals - P/E Multiple|Company Value to Net Income PRGO (perrigo.com)|ALVO: P/E Multiple|Market Cap to Earnings Liquidia Corp (LQDA)|Price to Earnings Ratio Galapagos Genomics|ANIP: Company Value to Net Income|P/E Multiple MNKD|Business Payback Period amphastar.com|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|SPRY - Price to Earnings Ratio|TBPH - Price to Earnings Ratio|Market Cap to Net Income AQST|SCPH: P/E Multiple|Tectonic Therapeutic (TECX) - P/E Multiple|TNXP (Tonix Pharmaceuticals Holding Corp.) - P/E Multiple|Price to Earnings Ratio SXT China (SXTC)|Price to Earnings Ratio EPRX (Eupraxia Pharmaceuticals)|Market Price to Net Income Ratio BHST|eXoZymes Inc - Price to Earnings Ratio|Company Value to Net Income ORMP|Entera Bio Corp - P/E Multiple|HYFT: Price to Earnings Ratio|ABVC: P/E Multiple|CPIX - Business Payback Period|Price to Earnings Ratio Quantum BioPharma Ltd|Market Cap to Earnings fibrogen.com FGEN|Price to Earnings Ratio Telomir Pharmaceuticals, Inc. (TELO)|Price to Earnings Ratio ranitherapeutics.com RANI|P/E Multiple SNYR (Synergy CHC)|Rallybio Corp (RLYB) - Market Cap to Earnings|Lexaria - P/E Multiple|PULM (pulmatrix.com) - Price to Earnings Multiple|PTHL: P/E Multiple|APM - Business Payback Period|LYRA (Lyra Therapeutics, Inc) - P/E Multiple|Price to Earnings Ratio TNF Pharma (TNFA)|P/E Multiple YCBD|P/E Multiple painreform.com (PRFX)|Price to Earnings Ratio Altamira Therapeutics Ltd. CYTO|Lipella Pharmaceuticals Inc - Price to Earnings Ratio|OPTN: Price to Earnings Ratio|Company Value to Net Income PIRS (Pieris Pharma)|PROC: P/E Multiple|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding|Price to Earnings Multiple SLRN (Acelyrin Inc.)|P/E Multiple TFFP